| Literature DB >> 33109299 |
Ioana Alina Cristea1, Florian Naudet2, John P A Ioannidis3.
Abstract
In the coronavirus disease 2019 (COVID-19) pandemic, a large number of non-pharmaceutical measures that pertain to the wider group of social distancing interventions (e.g. public gathering bans, closures of schools, workplaces and all but essential business, mandatory stay-at-home policies, travel restrictions, border closures and others) have been deployed. Their urgent deployment was defended with modelling and observational data of spurious credibility. There is major debate on whether these measures are effective and there is also uncertainty about the magnitude of the harms that these measures might induce. Given that there is equipoise for how, when and if specific social distancing interventions for COVID-19 should be applied and removed/modified during reopening, we argue that informative randomised-controlled trials are needed. Only a few such randomised trials have already been conducted, but the ones done to-date demonstrate that a randomised trials agenda is feasible. We discuss here issues of study design choice, selection of comparators (intervention and controls), choice of outcomes and additional considerations for the conduct of such trials. We also discuss and refute common counter-arguments against the conduct of such trials.Entities:
Keywords: Randomisation; randomised-controlled trials; research design and methods; statistics
Mesh:
Year: 2020 PMID: 33109299 PMCID: PMC7674786 DOI: 10.1017/S2045796020000992
Source DB: PubMed Journal: Epidemiol Psychiatr Sci ISSN: 2045-7960 Impact factor: 6.892
Aspects of social distancing interventions that can be considered to choose randomised comparisons
| Important aspects | Examples |
|---|---|
| Interventions and their dosing | Physical distance: 1 m (like in France or Italy), 1.5 m (like in Australia), 6 foot (like in US or UK), 3 , 6 m (maximum distance virus can reach upon forceful cough) |
| Timing and duration of implementation | Pre-emptively (before any cases have been detected), early in the course of the epidemic (define how early and how timing is decided, based on what features or measurements), late in the course of the epidemic (similarly define) |
| Sequencing and combination | How different interventions at different doses are sequenced (in what order) and how they are combined |
| Enforcement of adherence | Advice, intense messaging (how intense and by which stakeholders, with what processes and with what means and media), law with fines, law with strong penalties, law with imprisonment, law with capital punishment |
| Weaning process | Refers to all of the items discussed above (interventions and dosing, timing, sequencing and combination, enforcement of adherence) but in reverse order, trying to remove restrictions |
| Measurement of extent of adoption | No measurement, tracking of indicators (decide which indicators) |
| Use of response indicators/surrogates | Using or not tracking indicators (e.g. number of documented infections, hospitalisations or deaths) to modulate the interventions, add more interventions, remove interventions |
| Target group choice | Entire population, specific groups defined by age, occupation/workplace, perceived risk factors (e.g. underlying predisposing diseases), or setting (see below) |
| Setting choice | World-wide, country-wide, town-wide, facility-wide (e.g. nursing homes, hospitals), more precisely localised (if so, decide based on which features) |
Key features to consider for outcomes for randomised trials of social distancing
| Feature | Comment |
|---|---|
| Types of outcomes | Documented infections, hospitalisations or ICU hospitalisation for COVID-19, COVID-19 deaths, all deaths, quality of life indicators, impact on other diseases, impact on health utilisation, impact on social indicators (e.g. violence, unemployment) |
| Timing of measurement | Short-term, longer-term, determining carry-over effects and interactive effects from use of other interventions in parallel or in sequence |
| Data collection on outcomes | Passive, active, systematic, at different levels of intensity |
| Long-term relevance | Influence of short-term outcomes on longer-term prospects (e.g. few infections in the short term, but creating conditions for many more in the long term) |
| Cost-effectiveness | Strategies sustainable at short-, medium- and longer term; incorporation of cost-effectiveness metrics |
| Placing in context to broader gains and risks | From effects on economy, environment, society and health system at large |